CAESAREA, Israel - IceCure Medical Ltd. (NASDAQ:ICCM), a company specializing in cryoablation technology for tumor treatment, announced today that it has regained compliance with the Nasdaq's minimum bid price requirement. The Nasdaq Stock Market LLC confirmed that IceCure's ordinary shares maintained a closing bid price of $1.00 or higher for ten consecutive business days, satisfying the Nasdaq Listing Rule 5550(a)(2).
The ProSense® System developed by IceCure is a minimally invasive procedure that treats tumors by freezing, offering an alternative to surgical removal. This system is currently available for use in several countries, including the United States, Europe, and China, for approved indications such as breast, kidney, bone, and lung cancers.
The information for this article is based on a press release statement from IceCure Medical Ltd.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.